CRP and melanoma: Additionally, further blood cell ratios such as the lymphocyte-to-monocyte ratio (LMR) [14,17], the platelet-to-lymphocyte ratio (PLR) [18,19] and the derived neutrophil-to-lymphocyte ratio (dNLR) [20,21], as well as serological inflammatory parameters (e.g., the acute phase reactant C-reactive protein; CRP) have been assessed for their ability to predict progression and survival in melanoma patients [22,23].